I was born and raised in Waco, Texas and have lived in central Texas most of my life. My first career was a teacher/coach in the middle and high school after completing my BA in Mathematics at the University of North Texas. My second career as a statistician commenced after earning my PhD in Statistics at Baylor University. I joied Eli Lilly & Company in 2006 where I have been the lead statistician for early and late phase assets and a key contributor to successful US and global submissions, regulatory interactions, and commercialization work products. In my current role at Eli Lilly & Company, I provide consultation across multiple therapeutic areas and phases of development for clinical trial and clinical program optimization utilizing various tools and methods for adaptive study designs and adaptive clinical programs. I am blessed to be in a role where I can use my technical skills and also assist my colleagues, who may or may not have formal statistical training, understand complex statistical concepts. When not working, I am either spending time with my husband and children or engaged in some sort of sports or physical fitness activity; family time often involves a sport or outdoor activity. My journey as a wife, mother, educator, statistician, and athlete has always been and continues to be by the grace of God. I do all things through Christ and pray that my life may glorify Him.
Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy, Prostate Cancer and Prostatic Disease (2015) 18, 43-48; Author list: Claus Roehrborn, Melissa Spann, Myers, Cynthia Serviss, Leijus Hu, and Yan Jin.
Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder, Human Psychopharmacology (2011); Author list: J. Bodkin, Christer Allgulander, P, Llorca, Melissa Spann, Daniel Walker, James Russell, Susan Ball.
Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale", International Clinical Psychopharmacology (2011) Mar; 26(2): 75-83; Author list: David Sheehan, Kethy Harnett-Sheehan, Melissa Spann, Harry Thompson, Apuvura Prakash.
Sexual Function during Long-Term Duloxetine Treatment in Patients with Recurrent Major Depressive Disorder", Journal of Sexual Medicine (2011) Mar; 8(3): 773-82; Author list: A. Montejo, D. Perahia, Melissa Spann, F. Wang, D. Walker, C. Yang, M. Detke.
Duloxetine 60 mg/day for the prevention of depressive recurrences: post hoc analyses from a recurrence prevention study", International Journal of Clinical Practice. (2010); Author list: K. Kelin, M. Berk, Melissa Spann, D. Sagman, Joel Raskin, Daniel Walker, David Perahia.
Relationship between TSH levels in the normal range and short-term duloxetime efficacy", Journal of Affective Disorders. (2010); Author list: E. Corruble, Celine Goldberger, Melissa Spann.
A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: implications for the randomized withdrawl relapse prevention study design", Journal of Clinical Psychopharmacology (2009); Author list: P. Llorca, J. Bodkin, Melissa Spann, Susan Ball, James Russell.
Bayesian Adaptive Non-inferiority with Safety Assessment: Retrospective Case Study to Highlight Potential Benefits and Limitations of the Approach", Journal of Psychiatric Research (2008); Author list: Melissa Spann, Stacy R. Lindborg, John W. Seaman Jr., Robert W. Baker, Eduardo Dunayevich, Alan Brier.